LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
Tiago Fleming OuteiroKirsten HarveyAntonio Dominguez-MeijideEllen GerhardtPublished in: Biochemical Society transactions (2019)
The identification of genetic forms of Parkinson's disease (PD) has tremendously expanded our understanding of the players and mechanisms involved. Mutations in the genes encoding for alpha-synuclein (aSyn), LRRK2, and tau have been associated with familial and sporadic forms of the disease. aSyn is the major component of Lewy bodies and Lewy neurites, which are pathognomonic protein inclusions in PD. Hyperphosphorylated tau protein accumulates in neurofibrillary tangles in the brains of Alzheimer's disease patients but is also seen in the brains of PD patients. LRRK2 is a complex multi-domain protein with kinase and GTPase enzymatic activity. Since aSyn and tau are phosphoproteins, we review the possible interplay between the three proteins. Understanding the interplay between LRRK2, aSyn and tau is extremely important, as this may enable the identification of novel targets and pathways for therapeutic intervention.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- cerebrospinal fluid
- newly diagnosed
- randomized controlled trial
- protein protein
- genome wide
- patient reported outcomes
- early onset
- hydrogen peroxide
- late onset
- dna methylation
- amino acid
- nitric oxide
- hepatitis c virus
- mild cognitive impairment
- deep brain stimulation